Evidence map›Paper›PMID 41099970›Full record

ArticleJournal of neuro-oncology2025

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Vincent HarlayNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France. vincent.harlay@ap-hm.fr.
Céline BequetNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Romain AppayNeuropathology Department, AP-HM, Aix Marseille University, University Hospital Timone, Marseille, 13005, France.
Alexandre BertucciNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Gregorio PetrirenaNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Chantal CampelloNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Maryline BarriéNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Didier AutranNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Thomas GraillonNeurosurgery Department, AP-HM, INSERM, MMG, Aix-Marseille University, University Hospital Timone, Marseille, 13005, France.
Henry DufourNeurosurgery Department, AP-HM, INSERM, MMG, Aix-Marseille University, University Hospital Timone, Marseille, 13005, France.
Dominique Figarella-BrangerNeuropathology Department, AP-HM, Aix Marseille University, University Hospital Timone, Marseille, 13005, France.
Laetitia PadovaniRadiotherapy Department, AP-HM, Aix-Marseille University, University Hospital Timone, Marseille, 13005, France.
Anne BarlierLaboratory of Molecular Biology GEnOPé, BIOGENOPOLE, APHM, INSERM, MMG (U1251), Aix Marseille University, La Timone University Hospital, Marseille, France.
Isabelle NanniOncobiology Department, Aix-Marseille University, University Hospital Nord, Marseille, 13005, France.
Emeline TabouretNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.
Olivier ChinotNeuro-Oncology Department, AP-HM, Aix-Marseille University, University Hospital Timone, 264 Rue Saint Pierre, Marseille, 13005, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose"Biopsy-only" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.

methodsPatients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.

results137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).

conclusionAutonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.

Indexed as

Brain NeoplasmsGlioblastomaIsocitrate DehydrogenasePersonal AutonomyAdultAgedAged, 80 and overBiopsyFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesQuality of LifeIDH1 protein, humanIsocitrate DehydrogenaseAutonomy durationBiopsy-onlyFunctional statusGlioblastomaUnresectable

Identifiers

PMID41099970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.